JPMorgan Chase & Co. Cuts Repligen (NASDAQ:RGEN) Price Target to $200.00

Repligen (NASDAQ:RGEN) had its price target trimmed by JPMorgan Chase & Co. from $230.00 to $200.00 in a report released on Thursday, Benzinga reports. The firm currently has an overweight rating on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the stock. KeyCorp upped their target price on shares of Repligen from $210.00 to $220.00 and gave the company an overweight rating in a report on Thursday, February 15th. Stifel Nicolaus upped their target price on shares of Repligen from $165.00 to $207.00 and gave the company a buy rating in a report on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus target price of $197.75.

Repligen Stock Performance

NASDAQ RGEN traded up $0.74 during trading hours on Thursday, hitting $167.05. The company had a trading volume of 454,984 shares, compared to its average volume of 538,521. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.75 and a current ratio of 6.35. Repligen has a 1-year low of $110.45 and a 1-year high of $211.13. The company has a market cap of $9.33 billion, a PE ratio of 668.23, a price-to-earnings-growth ratio of 5.46 and a beta of 1.03. The business has a 50 day moving average of $180.81 and a 200-day moving average of $174.09.

Repligen (NASDAQ:RGEN) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). Repligen had a net margin of 2.44% and a return on equity of 3.95%. The business had revenue of $151.31 million during the quarter, compared to analysts’ expectations of $150.06 million. During the same period in the previous year, the company posted $0.64 earnings per share. Repligen’s quarterly revenue was down 17.1% on a year-over-year basis. As a group, equities research analysts expect that Repligen will post 1.46 EPS for the current year.

Insiders Place Their Bets

In other news, Director Karen A. Dawes sold 1,000 shares of the stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total value of $193,350.00. Following the sale, the director now directly owns 87,367 shares in the company, valued at $16,892,409.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Anthony Hunt sold 16,707 shares of Repligen stock in a transaction on Friday, March 8th. The shares were sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the transaction, the chief executive officer now owns 185,249 shares in the company, valued at approximately $36,575,562.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Karen A. Dawes sold 1,000 shares of Repligen stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total transaction of $193,350.00. Following the transaction, the director now owns 87,367 shares in the company, valued at approximately $16,892,409.45. The disclosure for this sale can be found here. Over the last three months, insiders have sold 25,597 shares of company stock worth $5,039,532. 1.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Repligen

Several hedge funds and other institutional investors have recently modified their holdings of RGEN. CWM LLC grew its position in shares of Repligen by 19.9% during the 1st quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 60 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Repligen by 0.3% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,178 shares of the biotechnology company’s stock worth $3,805,000 after acquiring an additional 62 shares during the period. abrdn plc lifted its stake in Repligen by 1.4% during the fourth quarter. abrdn plc now owns 5,192 shares of the biotechnology company’s stock valued at $934,000 after purchasing an additional 71 shares during the last quarter. Commerce Bank lifted its stake in Repligen by 4.5% during the fourth quarter. Commerce Bank now owns 1,683 shares of the biotechnology company’s stock valued at $303,000 after purchasing an additional 72 shares during the last quarter. Finally, Quadrant Capital Group LLC lifted its stake in Repligen by 15.1% during the fourth quarter. Quadrant Capital Group LLC now owns 649 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 85 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.